Evidence map›Paper›PMID 29048990›Full record

ArticleHuman vaccines & immunotherapeutics2018

Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.

Esteban Cruz, Joel Cain, Ben Crossett, Veysel Kayser

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Antigenic characterization of influenza and SARS-CoV-2 viruses.Analytical and bioanalytical chemistry · 2022
    Review
  10. Vaccines and vaccination: history and emerging issues.Human vaccines & immunotherapeutics · 2021
    Review
  11. Article
  12. Review
  13. Review
  14. MASS SPECTROMETRY IN VIROLOGICAL SCIENCES.Mass spectrometry reviews · 2020
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Why Glycosylation Matters in Building a Better Flu Vaccine.Molecular & cellular proteomics : MCP · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Esteban Cruza Faculty of Pharmacy, The University of Sydney , Sydney NSW , Australia.
Joel Cainb School of Life and Environmental Sciences, The University of Sydney , Sydney NSW , Australia.
Ben Crossettc Mass Spectrometry Core Facility, The University of Sydney , Sydney NSW , Australia.
Veysel Kaysera Faculty of Pharmacy, The University of Sydney , Sydney NSW , Australia.
University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study of influenza virus evolution in humans has revealed a significant role of glycosylation profile alterations in the viral glycoproteins - hemagglutinin (HA) and neuraminidase (NA), in the emergence of both seasonal and pandemic strains. Viral antigenic drift can modify the number and location of glycosylation sites, altering a wide range of biological activities and the antigenic properties of the strain. In view of the key role of glycans in determining antigenicity, elucidating the glycosylation profiles of influenza strains is a requirement towards the development of improved vaccines. Sequence-based analysis of viral RNA has provided great insight into the role of glycosite modifications in altering virulence and pathogenicity. Nonetheless, this sequence-based approach can only predict potential glycosylation sites. Due to experimental challenges, experimental confirmation of the occupation of predicted glycosylation sites has only been carried out for a few strains. Herein, we utilized HCD/CID-MS/MS tandem mass spectrometry to characterize the site-specific profile of HA of an egg-grown H1N1 reference strain (A/New Caledonia/20/1999). We confirmed experimentally the occupancy of glycosylation sites identified by primary sequence analysis and determined the heterogeneity of glycan structures. Four glycosylation sequons on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, N104, N142 and N177) of the protein are occupied. Our results revealed a broad glycan microheterogeneity, i.e., a great diversity of glycan compositions present on each glycosite. The present methodology can be applied to characterize other viruses, particularly different influenza strains, to better understand the impact of glycosylation on biological activities and aid the improvement of influenza vaccines.

Indexed as

Amino Acid SequenceAnimalsAntigens, ViralChickensEgg HypersensitivityGlycosylationHemagglutinin Glycoproteins, Influenza VirusHemagglutininsHumansInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesNeuraminidaseTandem Mass SpectrometryVirulenceAntigens, ViralHemagglutinin Glycoproteins, Influenza VirusHemagglutininsInfluenza VaccinesNeuraminidaseantigenic siteCIDglycosite modificationH1N1HCDhemagglutinininfluenza glycosylationmass spectrometry

Identifiers

PMID29048990
PMCPMC5861804
OpenAlexW2767164921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.